📈 Price History

Ratio Health

— Excellent

— Good

— Average

— Poor

By Category

📊 Sector Averages

About

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. The Research Models and Services segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including genetically engineered models and services, insourcing solutions, and research animal diagnostic services; and engages in development and production of cell therapies. The Discovery and Safety Assessment segment offers in vitro and in vivo discovery services for the discovery, development, and safety testing of novel drugs, molecule compounds, oligonucleotides, and biotherapeutics, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services; and vivarium space services. The Manufacturing Solutions segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products; offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and contract development and manufacturing products and services. The company has strategic collaborations with Parker Institute for Cancer Immunotherapy and Children’s Hospital Los Angeles across its contract development and manufacturing organization; and Medigen Vaccine Biologics Corp for developing next-generation multivalent enterovirus vaccine, enhance global regulatory readiness, and support IND-enabling non-clinical studies. Additionally, it has a strategic alliance with Francis Crick Institute (Crick), Inc. for the development of Antibody-Drug Conjugate (ADC) drug discovery and development. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.

Key Ratios Snapshot

📈 Growth Pattern

⚡ Latest Quarter —

See full financials →

📊 Quick Scorecard

Loading…

🔍 Concall Decoded

🎙 Management Tone Tracker Confident Specific ~ Volatile 4 quarters analysed

Q2 2025

Confident Specific

Management repeatedly described the quarter as 'solid' and 'meaningfully exceeding' expectations, using specific figures like 'raised guidance by $0.55 at midpoint' and 'DSA net bookings up mid-single-digit year-over-year.' They also emphasized stabilization but were careful to describe the recovery as 'not linear' and took a 'measured and prudent approach' to guidance.

Q3 2025

Cautious

Management consistently uses phrases like 'guardedly optimistic', 'still some uncertainty', 'too early to provide even a preliminary outlook', and 'we will continue to remain cautious'. They emphasize positive signals (improved biotech funding, rising proposals) but repeatedly hedge on timing and magnitude of recovery.

Q4 2025

Cautious

Management frequently used phrases like 'cautiously optimistic', 'not linear', and 'dependent on continued momentum'. They hedged the 2026 revenue outlook (down 1% to flat) and stressed that Q4 bookings benefits would not materialize until H2 2026. The tone balanced positive demand signals with explicit warnings about near-term headwinds.

Q1 2026 latest

Confident Specific

Management repeatedly uses phrases like 'clear line of sight', 'cautiously optimistic', and provides specific numbers (1.04x book-to-bill, $2.06 EPS, $300M cumulative cost savings) while acknowledging near-term headwinds such as '260 bps margin decline' and 'low single-digit organic revenue decline'.

Guidance Reliability Pending · <3Q data

Investor Lens

The investment thesis appears stronger after this call, driven by clear line of sight to margin expansion from recent portfolio actions (K.F. acquisition, divestitures) and the $300M cost savings program. Demand is improving with biotech funding recovery and large pharma returning to growth, though small biotech remains tepid. The new CEO's 'Pathway to Purpose' strategy provides a disciplined framework, and the CFO's quantified accretion creates near-term earnings visibility. Key risks include continued FX headwinds, timing of NHP cost normalization, and slower-than-expected biotech revenue inflection. Watch for Q2 sequential margin improvement and bookings momentum in DSA as the most telling indicators next quarter.

AI-generated concall tone analysis · Updated 2026-06-08 · Not investment advice

🎙 Management Tone Confident Specific ~ Volatile 4 quarters Full tone analysis in Intelligence →

📊 MIXED Charles River Labs Q1 2026: Revenue $996M, EPS $2.06, organic decline 1.5%.

Revenue & Profitability

First quarter 2026 revenue was $996 million, up 1.2% reported but down 1.5% organically. Non-GAAP EPS was $2.06, down 12% year-over-year. Non-GAAP operating margin was 16.3%, a decrease of 280 basis points. Free cash flow was negative $15 million. For full-year 2026, the company reaffirmed organic revenue decline of 0.5%-1.5% and EPS of $10.80-$11.30 (5-10% growth).

Outlook

Management expressed cautious optimism, noting stabilization in the overall biopharma demand environment and pockets of improvement in both large pharma and biotech. Biotech funding has improved over the last two quarters, and pharma restructuring is largely complete. Government funding uncertainty (NIH) has had a modest impact. The company expects DSA to return to organic growth in the second half of 2026.

Growth Drivers

Key growth drivers include the DSA segment (net book-to-bill of 1.04x, backlog of $1.92B), strong demand in Microbial Solutions (Endosafe, Celsis), and expansion of NAMs capabilities. Biotech demand is improving, with mid-sized and larger biotechs gaining better access to capital. China small model demand was solid, particularly from mid-tier biotech and CRO clients. The divestiture of CDMO and Cell Solutions refocuses the portfolio on core competencies.

Balance Sheet & CapEx

Capital expenditure in Q1 2026 was $56 million, or approximately 5.6% of revenue. Full-year free cash flow guidance remains $375-$400 million. The company is investing in AI, lab automation, the Apollo platform, and NAMs capabilities. Organic investments are directed toward strategic locations and client-centric tools, with further expansion in technology and digitization.

Margins

Q1 2026 non-GAAP operating margin declined 280 bps to 16.3% due to headwinds from stock compensation, NHP costs, and timing. Management expects significant margin improvement in the second half, with H2 margins over 500 bps higher than H1, driven by acquisitions, divestitures, and efficiency initiatives. Full-year margin expansion of 120-150 bps is expected. The company has generated cumulative cost savings of over $300 million annualized, with $100 million incremental in 2026.

Key Risks

Risks highlighted include: continued tepid funding environment for early-stage biotechs, government funding uncertainty (NIH), foreign exchange headwinds (strengthening USD), discrete margin headwinds in Q1 (NHP costs, stock compensation), and the impact of client-specific challenges (e.g., loss of a large commercial client in CDMO). Geopolitical risk in China was also mentioned regarding potential expansion.

Generated by AI · Q1 2026 results · Not investment advice

✓ 📞 Earnings Call Transcripts (5 quarters) submit a missing quarter

🔍

🔎 See cross-company document search → ?

📞 Earnings Call Transcripts (5)

Q2 2026 Q2 2026 2026-08-05

Second quarter results exceeded expectations, with organic revenue growth, margin expansion, and strong DSA bookings. Full-year guidance was raised for revenue, EPS, and free cash flow, supported by portfolio refinement and robust biopharma demand.

Q1 2026 Q1 2026 2026-05-07

Q1 2026 saw revenue of $996M (+1.2% YoY), but organic revenue declined 1.5% and EPS fell 12% to $2.06. Strategic portfolio actions and cost savings are expected to drive 120-150 bps margin expansion in 2026, with most improvement in the second half.

Q4 2025 Q4 2025 2026-02-18

Q4 and full year 2025 results met the upper end of guidance, with organic revenue declines but strong DSA bookings and improved biotech funding in H2. 2026 guidance anticipates flat to slightly negative organic revenue, margin improvement from acquisitions, and a return to DSA growth in H2.

Q3 2025 Q3 2025 2025-11-05

Q3 revenue declined slightly year-over-year, but demand trends stabilized and proposal activity improved, especially in biotech. Strategic actions include divesting non-core assets, new cost savings, and a $1B stock repurchase plan. 2025 guidance narrowed, with EPS at the top end of the range.

Q2 2025 Q2 2025 2025-08-06

Second quarter results exceeded expectations with revenue of $1.03 billion and EPS up 11.4%. Guidance for 2025 was raised, reflecting strong DSA performance, cost savings, and favorable FX, though H2 faces headwinds from CDMO client loss and higher staffing costs.

📊 Analysis Methodology

This comprehensive investment analysis was conducted using The Finmagine™ Stock Analysis & Ranking Methodology, a proprietary framework that systematically evaluates stocks across five critical dimensions: Financial Health, Growth Prospects, Competitive Positioning, Management Quality, and Valuation.

🎯

Discover Our Proven Investment Framework Learn how we analyze and rank stocks using advanced quantitative models, multi-dimensional scoring systems, and dynamic discriminatory ranking techniques that have guided successful investment decisions across market cycles.

📊 Explore The Finmagine™ Methodology

A comprehensive, bias-free framework for analyzing and ranking stocks by Financial Strength, Growth Potential, Competitive Edge, Management Quality, and Value.

⚠️ Important Disclaimers — Please read without fail.

Investment Risk:
Investing in securities, including US equities and ETFs, involves inherent risks including the potential loss of principal. All investments are subject to market fluctuations, economic conditions, regulatory changes, and other factors that may affect their value. Past performance is not indicative of future results. This analysis is provided for informational and educational purposes only and should not be construed as investment advice under any circumstances.

No Investment Recommendation:
This analysis does not constitute, nor should it be interpreted as, an offer, solicitation, or recommendation to buy, sell, or hold any securities or financial products. Investors are strongly advised to conduct their own independent research and due diligence and to consult with a licensed financial advisor or an SEC-registered investment adviser before making any investment decisions, taking into account their individual financial situation, risk tolerance, and investment objectives.

Not SEC-Registered:
Finmagine is not registered as an investment adviser with the U.S. Securities and Exchange Commission (SEC) or any state securities authority. Nothing on this platform constitutes investment advice as defined under the Investment Advisers Act of 1940.

Conflict of Interest Disclosure:
The author and/or analyst may currently hold or have previously held positions in the securities discussed. Any such positions are not intended to influence the objectivity or independence of the analysis. This research is produced independently and is not sponsored, endorsed, or commissioned by any company or institution.

Information Sources:
The analysis is based on publicly available information including SEC filings (10-K, 10-Q), annual reports, management commentary, and publicly available financial data. Information is believed to be accurate as of the date of publication but may be subject to change without notice. Readers are encouraged to independently verify all information before acting upon it.

Forward-Looking Statements:
This analysis may contain forward-looking statements, forecasts, or projections that are inherently subject to risks, uncertainties, and assumptions. Actual results may differ materially from those expressed or implied. Finmagine does not undertake any obligation to update such statements in the future.

Limitation of Liability:
The content is provided "as is" without any warranties, express or implied. Finmagine expressly disclaims any liability for errors, omissions, or any losses incurred as a result of reliance on the information provided. Readers assume full responsibility for their investment decisions.